← FDA DRUG APPROVALS

FDA ANDA · ANDA084270

TRIAMCINOLONE

Sponsor: WATSON LABS

APPLICATION
ANDA084270
TYPE
ANDA
ORIGINAL APPROVAL
1977-02-08
LATEST ACTION
1999-08-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TRIAMCINOLONEDiscontinued
TRIAMCINOLONE 4MG · TABLET · ORAL

Approval history

1999-08-26Manufacturing (CMC) · Supplement 41AP
1998-10-20Manufacturing (CMC) · Supplement 25AP
1995-01-27Labeling · Supplement 39AP
1994-05-05Labeling · Supplement 38AP
1991-08-07Manufacturing (CMC) · Supplement 34AP
1991-05-15Labeling · Supplement 37AP
1991-03-15Labeling · Supplement 36AP
1991-01-28Manufacturing (CMC) · Supplement 35AP
1990-06-29Manufacturing (CMC) · Supplement 33AP
1989-04-18Manufacturing (CMC) · Supplement 31AP
1989-04-18Manufacturing (CMC) · Supplement 32AP
1989-04-10Bioequivalence · Supplement 30AP
1985-05-15Manufacturing (CMC) · Supplement 29AP
1985-05-15Manufacturing (CMC) · Supplement 28AP
1985-03-11Manufacturing (CMC) · Supplement 27AP
1981-09-25Manufacturing (CMC) · Supplement 26AP
1977-02-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →